Home
Current Issue
Archives
Guidelines for Authors
Classified Ads
Links
Search PubMed
Subscriptions
Subscriber Registration
Guidelines for Website Users
JRheum Update Service
Contact Info
|
 |
Case Report
Anti-Androgen Treatment of Prostatic Carcinoma
May Be a Risk Factor for Development of
Rheumatoid Arthritis
JANET E. POPE, MALA JONEJA, and PAUL HONG
ABSTRACT.
There are many rheumatic paraneoplastic syndromes. The association between prostate carcinoma and subsequent development of rheumatoid arthritis (RA) has not been reported. We describe 3 cases of men developing inflammatory arthritis after anti-androgen manipulation for treatment of prostate carcinoma. None had diagnoses supporting other connective tissue disease or crystal arthritis. Only one patient had a weakly positive rheumatoid factor, and another had a positive antinuclear antibody. The cases fulfilled 1987 American College of Rheumatology criteria for RA. The onset of joint symptoms was within weeks to 9 months of starting therapy to suppress testosterone [2 received leuprolide acetate (Lupron) and one cyproterone acetate (Androcur)]. Review of the literature yielded no reports of prostate carcinoma associated with paraneoplastic RA. We review the literature with respect to associations of paraneoplastic RA and prostate carcinoma and discuss published data in the context of the hypothesis of lower testosterone and increased risk of RA. (J Rheumatol 2002;29:2459-62)
Key Indexing Terms:
HORMONE TREATMENT
PROSTATE
RISK FACTOR
RHEUMATOID ARTHRITIS
From the Division of Rheumatology, Department of Medicine, the University of Western Ontario, London, Ontario, Canada.
J.E. Pope, MD, MPH, FRCPC, Associate Professor of Medicine;
M. Joneja, MD, FRCPC; P. Hong, BSc Hons.
Address reprint requests to Dr. J.E. Pope, Rheumatology Centre, St. Joseph's Health Centre, 268 Grosvenor Street, Box 5777, London, Ontario N6A 4V2. E-mail: janet.pope@sjhc.london.on.ca
Submitted September 24, 2001; revision accepted May 29, 2002.
|
